查詢結果分析
來源資料
相關文獻
- The Status and Prospects of Radiopharmaceutical Research for Targeted Radiotherapy in Taiwan
- Postoperative Radiotherapy of Adult Supratentorial High-grade Astrocytoma
- Malignant Primary Extragonadal Germ Cell Tumors of Mediastinum--An Analysis of Clinical and Radiological Features in 15 Cases
- Radiation Therapy in Primary Central Nervous System Lymphoma
- Implications of a Failed Prospective Trial of Adjuvant Therapy after Radical Hysterectomy for Stage Ib-IIa Cervical Carcinoma with Pelvic Node Metastases
- 攝護腺癌之傳統放射線治療--長庚紀念醫院十四年之經驗
- Preoperative Radiotherapy in Patients with Lower Rectal Cancer:Results of Sphincter-Preservation, Treatment Outcome and Morbidities
- A Phase Ⅱ Study of Neoadjuvant Interferon Alfa-2B and Concurrent Interferon and Radiotherapy in Primary Untreated Undifferentiated Carcinoma of Nasopharynx
- 成人低惡性度顱內星狀細胞瘤之術後放射治療
- The Role of Radiotherapy for Advanced Non-Small Cell Lung Cancer
第1筆 /總和 1 筆
/ 1 筆
頁籤選單縮合
題名 | The Status and Prospects of Radiopharmaceutical Research for Targeted Radiotherapy in Taiwan=臺灣放射治療用核醫藥物研發現況與展望 |
---|---|
作者 | 王世楨; 丁幹; Wang, Shyh-jen; Ting, Gann; |
期刊 | 核子醫學雜誌 |
出版日期 | 20021200 |
卷期 | 15:4 2002.12[民91.12] |
頁次 | 頁195-200 |
分類號 | 414.93 |
語文 | eng |
關鍵詞 | 放射治療; 核醫藥物; 釔-90利比多; 錸-188利比多; 錸-188微粒; 錸-188-HEDP; 錸-188硫膠體; 娦Y-lipiodol; Radiotherapy; Radiopharmaceutical; □Re-lipiodol; □Re-microsphere; □Re-HEDP; □Re-sulfur colloid; |
中文摘要 | 治療用核子醫學在過去十年間已快速發展成腫瘤治療的方法,許多能特異性追蹤腫瘤的核醫藥物被上市用於癌症放射治療。由於國外輸入不易及價格昂貴,大部份治療用核醫藥物未能臨床用於臺灣病患,有鑑於此,核能研究所近年來致力於發展治療用核醫藥物,並已有部份成果。釔-90、錸-188標幟利比多 (Lipiodol)以及錸-188微粒的研製可應用於肝癌治療;錸-188-HEDP之研發可應用於惡性腫瘤轉移產生的骨痛治療;錸-188硫膠體之研發可應用於惡性腫瘤腹水治療。這些治療用核醫藥物正進行臨床前研究,後續臨床研究即將展開。 |
英文摘要 | Therapeutic nuclear medicine has grown rapidly as a treatment modality in oncology in last decade. A varietyof specific tumor-seeking radiopharmaceuticals have been commercialized for radiotherapy. However, most of these therapeutic radiopharmaceuticals are not applied to patients clinically in Taiwan because of difficulty in importing these drugs from other countries and their high expense. Therefore, the Institute of Nuclear Energy Research (INER) in Taiwan has been putting their efforts on developing these therapeutic radiopharmaceuticals and several kinds of therapeutic radiopharmaceuticals have been developed successfully in the past few years. 90Y-lipiodol, 188Re-lipiodol and 188Re-microsphere are developed for the therapy of hepatoma, I88Re-HEDP for metastatic bone pain and 188Re-sulfur colloid for malignant ascites. Pre-clinical studies of these radiopharmaceuticals are being carried out and clinical trials will be conducted soon. |
本系統之摘要資訊系依該期刊論文摘要之資訊為主。